Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis

OBJECTIVE: To test whether inhibition of sclerostin by a targeted monoclonal antibody (Scl-Ab) protects from bone and cartilage damage in inflammatory arthritis. Sclerostin is a potent inhibitor of bone formation and may be responsible for the low level of bone repair in patients with rheumatoid art...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiao-Xiang, Baum, Wolfgang, Dwyer, Denise, Stock, Michael, Schwabe, Kay, Ke, Hua-Zhu, Stolina, Marina, Schett, Georg, Bozec, Aline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786639/
https://www.ncbi.nlm.nih.gov/pubmed/23666928
http://dx.doi.org/10.1136/annrheumdis-2013-203345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786639/
https://www.ncbi.nlm.nih.gov/pubmed/23666928
http://dx.doi.org/10.1136/annrheumdis-2013-203345

Ejemplares similares